Associated Papers
Functional Analysis of Rare RAS Variants of Unknown Significance.
Park S et al.
Cancer Research Communications, 2025
40970755 (PubMed )
Supplement: crc-25-0188_supplementary_table_s5_suppst5.xlsx › Supplementary_Table_S5
Clinical Implications of Circulating Tumor DNA in Multiple Myeloma and Its Precursor Diseases.
Park SS et al.
Annals of Laboratory Medicine, 2025
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
Electrochemical biosensors for analysis of DNA point mutations in cancer research.
Ondraskova K et al.
Analytical and Bioanalytical Chemistry, 2023
An ultra-sensitive method to detect mutations in human RAS templates.
Li S et al.
Small Gtpases, 2022
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
Le Calvez-Kelm F et al.
Oncotarget, 2016
The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.
Svaton M et al.
Anticancer Research, 2016
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
Kiel C et al.
Molecular Systems Biology, 2014
24803665 (PubMed )
Supplement: MSB-10-5-727-s13.xls › energies
Identification of candidate genes for lung cancer somatic mutation test kits.
Chen Y et al.
Genetics and Molecular Biology, 2013
Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
Yamaguchi F et al.
Lung Cancer (amsterdam, Netherlands), 2012
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.
Benesova L et al.
Anticancer Research, 2010
Select a paper to view details